Co-Target(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T84894 | Target Info | |||
| Target Name | Casein kinase II (CSNK2) | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | NO-GeName | ||||
| UniProt ID | |||||
| Co-Targets of This Target | Top | |||||
|---|---|---|---|---|---|---|
| Co-Target Name | Fms-like tyrosine kinase 3 (FLT-3) | Successful Target | ||||
| UniProt ID | FLT3_HUMAN | |||||
| Gene Name | FLT3 | |||||
| Synonyms |
Stem cell tyrosine kinase 1; STK1; STK-1; Receptor-type tyrosine-protein kinase FLT3; Fetal liver kinase-2; FLT-3; FLK2; FLK-2; FL cytokine receptor; CD135
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 55 nM | [1] | ||
| Co-Target Name | Serine/threonine-protein kinase pim-1 (PIM1) | Clinical trial Target | ||||
| UniProt ID | PIM1_HUMAN | |||||
| Gene Name | PIM1 | |||||
| Synonyms |
Pim-1 proto-oncogene, serine/threonine kinase; PIM
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 46 nM | [1] | ||
| Co-Target Name | Serine/threonine-protein kinase pim-2 (PIM2) | Clinical trial Target | ||||
| UniProt ID | PIM2_HUMAN | |||||
| Gene Name | PIM2 | |||||
| Synonyms |
Pim-2h; PIM2
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 186 nM | [2] | ||
| Co-Target Name | CDC-like kinase 2 (CLK2) | Patented-recorded Target | ||||
| UniProt ID | CLK2_HUMAN | |||||
| Gene Name | CLK2 | |||||
| Synonyms |
Dual specificity protein kinase CLK2
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 3.8 nM | [3] | ||
| Co-Target Name | Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) | Patented-recorded Target | ||||
| UniProt ID | DYR1B_HUMAN | |||||
| Gene Name | DYRK1B | |||||
| Synonyms |
Minibrain-related kinase; MIRK; Dual specificity tyrosine-phosphorylation-regulated kinase 1B
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 6.4 nM | [4] | ||
| Co-Target Name | Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) | Patented-recorded Target | ||||
| UniProt ID | DYR1A_HUMAN | |||||
| Gene Name | DYRK1A | |||||
| Synonyms |
hMNB; Protein kinase minibrain homolog; MNBH; MNB; HP86; Dual specificity tyrosine-phosphorylation-regulated kinase 1A; Dual specificity YAK1-related kinase; DYRK
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 6.8 nM | [4] | ||
| Co-Target Name | NF-kappa-B-activating kinase (TBK1) | Patented-recorded Target | ||||
| UniProt ID | TBK1_HUMAN | |||||
| Gene Name | TBK1 | |||||
| Synonyms |
TANK-binding kinase 1; T2K; Serine/threonine-protein kinase TBK1; NAK
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 35 nM | [1] | ||
| Co-Target Name | Death-associated protein kinase 3 (DAPK3) | Literature-reported Target | ||||
| UniProt ID | DAPK3_HUMAN | |||||
| Gene Name | DAPK3 | |||||
| Synonyms |
Zipper-interacting protein kinase; ZIPK; ZIP-kinase; MYPT1 kinase; DAP-like kinase; DAP kinase 3
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 17 nM | [1] | ||
| Co-Target Name | CDC-like kinase 3 (CLK3) | Literature-reported Target | ||||
| UniProt ID | CLK3_HUMAN | |||||
| Gene Name | CLK3 | |||||
| Synonyms |
Dual specificity protein kinase CLK3
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 41 nM | [1] | ||
| Co-Target Name | Homeodomain-interacting protein kinase 3 (HIPK3) | Co-Target | ||||
| UniProt ID | HIPK3_HUMAN | |||||
| Gene Name | HIPK3 | |||||
| Synonyms |
Androgen receptor-interacting nuclear protein kinase; ANPK; Fas-interacting serine/threonine-protein kinase; FIST; Homolog of protein kinase YAK1
Click to Show/Hide
|
|||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 45 nM | [1] | ||
| Co-Target Name | Cyclin dependent kinase 1-G2/mitotic specific cyclin B complex (CDK1-CCNB) | Co-Target | ||||
| UniProt ID | CDK1_HUMAN-CCNB1_HUMAN/CCNB2_HUMAN/CCNB3_HUMAN | |||||
| Gene Name | CDK1-CCNB1/CCNB2/CCNB3 | |||||
| Representative Drug(s) | CX-4945 | Drug Info | IC50 = 56 nM | [1] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2011 Jan 27;54(2):635-54. | ||||
| REF 2 | 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92. | ||||
| REF 3 | Novel non-ATP competitive small molecules targeting the CK2 alpha/beta interface. Bioorg Med Chem. 2018 Jul 15;26(11):3016-20. | ||||
| REF 4 | 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site. J Med Chem. 2019 Feb 28;62(4):1803-1816. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.